Skip to main content

Table 2 Univariate and multivariate analysis of baseline characteristics with HCC development

From: Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis

  Univariant analysis p-value Multivariant analysis p-value
HR (95% CI) HR (95% CI)
Age 1.00 (0.99–1.01) NS   
Gender:male/female 3.11 (0.99–9.72) NS   
Child-Pugh score: A/B 0.48 (0.21–1.10) NS   
ADV-containing/Non-ADV-treatment 0.18 (0.09–0.43) < 0.05 0.18 (0.07–0.45) < 0.05
Total bilirubin: <  24/≥ 24 (μmol/L) 0.52 (0.19–1.41) NS   
HBV DNA: < 4/≥ 4 (log10 copies/mL) 0.85 (0.41–1.76) NS   
HBeAg: Positive/negative 1.16 (0.54–2.50) NS   
  1. HBeAg hepatitis B e antigen